Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors.

Genes - 9 Nov 2022

Schenkel Laila C, Mathew Joseph, Hirte Hal, Provias John, Paré Guillaume, Chong Michael, Grafodatskaya Daria, McCready Elizabeth

Abstract excerpt

Molecular biomarkers, such as IDH1/IDH2 mutations and 1p19q co-deletion, are included in the histopathological and clinical criteria currently used to diagnose and classify gliomas. IDH1/IDH2 mutation is a common feature of gliomas and is associated with a glioma-CpG island methylator phenotype (CIMP). Aberrant genomic methylation patterns can also be used to extrapolate information about copy number variation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36360312
DOI: 10.3390/genes13112075
PMCID: PMC9690723

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors.PMID 36360312Read ↗

DNA Methylation Profiling in IDH-Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation.Semantic proximity Read ↗

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.Semantic proximity Read ↗

Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma.Semantic proximity Read ↗

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.Semantic proximity Read ↗

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.Semantic proximity Read ↗

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risksSemantic proximity Read ↗

Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical ImplicationsSemantic proximity Read ↗

Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.Semantic proximity Read ↗

DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomasSemantic proximity Read ↗

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Semantic proximity Read ↗

Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.